生物谷援引美通社北卡罗来纳州达勒姆7月2日电：对患有胃肠道间质瘤 (GIST) 的罕见癌症患者来说，伊马替尼 (Gleevec(R)) 药物的使用已经较先前的疗法产生了具有革命性意义的改进。然而，尽管采用了伊马替尼，在有些患者中，癌细胞还是会立即或在出现初始反应后继续增长。The Oncologist6月期的一篇文章关注了近期对伊马替尼抗药性（包括可能在不久的将来开展对 GIST 个性化治疗的结果）原因的研究。
根据新的发现，Stefan Sleijfer 博士及其在荷兰鹿特丹伊拉兹马斯大学医学中心 (Erasmus University Medical Center) 的同事的论文得出结论：“在治疗受难以用伊马替尼治疗疾病时已经采取了几种策略，可以预测，在这一发现的基础上，将开发出其他积极的系统疗法。”
胃肠道间质瘤是罕见的胃肠道癌症。如果发现得及时，该疾病可以通过手术进行治疗。过去，则对更晚期的 GIST 病例进行标准化疗。尽管如此，治疗结果却没有患有其他类型癌症的患者的治疗那么理想。
原始出处:
The Oncologist, Vol. 12, No. 6, 719-726, June 2007; doi:10.1634/theoncologist.12-6-719
Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment
Stefan Sleijfer, Erik Wiemer, Caroline Seynaeve, Jaap Verweij
Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Key Words. GIST • Imatinib • Resistance • Sunitinib
Correspondence: Stefan Sleijfer, M.D., Ph.D. Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Telephone: 31-010-4391733; Fax: 31-010-4391003; e-mail: s.sleijfer@erasmusmc.nl
Gastrointestinal stromal tumor (GIST) is one of the first solid tumor types in which a tyrosine kinase inhibitor, imatinib, has become standard of care for patients with advanced disease. Although imatinib yields antitumor activity in the vast majority of patients, it is likely that all patients eventually experience progressive disease given enough time. In recent years, major progress has been made in the elucidation of mechanisms conferring resistance to imatinib that result in progressive disease. Insight into these resistance mechanisms has already resulted in the availability of strategies that can be applied in cases of progressive disease and it is likely that more approaches will be defined in the next years. Additionally, it can be anticipated that in the near future treatment will be guided according to factors determining sensitivity to imatinib. This review focuses on the factors inducing imatinib resistance that have been elucidated so far, the currently available and potential novel treatment options for patients with progressive disease, and how insight into resistance mechanisms may allow individualized treatment in the near future for patients with advanced GISTs.
Disclosure of potential conflicts of interest is found at the end of this article.
